ESTRO 2022 - Abstract Book

S1137

Abstract book

ESTRO 2022

Conclusion The study showed 2% absolute difference in DFS at 24 months between RECIST 1.1 and SRE in a population with low event rate. Further investigation of the differences is needed in population with higher event rate to understand impact of this transition.

PO-1342 Retrospective validation of new prognostic classification in endometrial cancer

I. Visus 1 , D. Aldabe 2 , S. Lapeña 3 , O. Tarrio 3 , S. Aguirre 3 , J.C. Muruzabal 3 , M. Barrado 1 , A. Sola 1 , E. Villafranca 1 , E. Martinez 1

1 Complex Hospital of Navarre, Radiation Oncology, Pamplona, Spain; 2 La Paz Univertisty Hospital, Radiation Oncology, Madrid, Spain; 3 Complex Hospital of Navarre, Gyneacology and Obstetrics, Pamplona, Spain Purpose or Objective To assess correlation with prognostic risk groups with disease free survival (DFS) and overall survival (OS) in patients with endometrial cancer (EC) and to study the impact of histological subtypes in DFS and OS inside high-risk group. Materials and Methods We performed a retrospective analysis of patients diagnosed with EC within a single center multidisciplinary unit of gynecology cancer from 2010 to 2018. Patients were treated with surgery and depending on clinical and pathological factors with adjuvant treatment. This treatment was chosen, in general terms, based on the prognostic risk classification: low risk: no adjuvant; intermediate risk: adjuvant brachytherapy; high risk: EBRT and brachytherapy with or without chemotherapy. With SPSS v25, survival rates were performed using Kaplan Meier mode and a Log-rank test was performed to compare the survival curves of different groups. Results 448 patients were analyzed. The mean age was 65,6 years and the median follow-up was 38 months. 3 and 5 years DFS is 86% and 79%. The OS at 3 and 5 years is 89% and 83%. Figure 1 shows the DFS and OS based on the prognostic risk groups. We also carry out a survival analysis of patients from the high-risk group based on the histological type (Figure 2). With a Chi-square value of 22,7, the Log-rank test shows statistically significant differences between these patients.